biostudies-literatureWang LJKaohsiung Chang Gung Memorial Hospital227https://www.ebi.ac.uk/biostudies/studies/S-EPMC8877879biostudies-literatureUnknown12(2)This study aimed to examine whether probiotics supplements using Bifidobacterium bifidum (Bf-688) can improve clinical characteristics and gut microbiomes among patients with attention-deficit/hyperactivity disorder (ADHD). This open-label, single-arm trial consisted of 30 children aged 4-16 years who met the criteria for ADHD diagnosis. Each subject took Bf-688, with one sachet in the morning and one in the evening (daily bacteria count 5 × 109 CFUs), for 8 weeks. Patients' clinical symptoms were assessed using the Swanson, Nolan, and Pelham Rating Scale (SNAP-IV). We collected stool samples at the baseline, the 8th week, and the 12th week for gut microbiota examination. During the 8-week Bf-688 supplement period, patients' inattention symptoms and hyperactivity/impulsivJournal of personalized medicineEffect of Bifidobacterium bifidum on Clinical Characteristics and Gut Microbiota in Attention-Deficit/Hyperactivity Disorder.PMC8877879CMRPG8K0761 & CMRPG8M0031CMRPG8K0761 & CMRPG8M0031Chou WJLee SYTsai CSKuo HCWang LJYang CYfalseEffect of Bifidobacterium bifidum on Clinical Characteristics and Gut Microbiota in Attention-Deficit/Hyperactivity Disorder.This study aimed to examine whether probiotics supplements using Bifidobacterium bifidum (Bf-688) can improve clinical characteristics and gut microbiomes among patients with attention-deficit/hyperactivity disorder (ADHD). This open-label, single-arm trial consisted of 30 children aged 4-16 years who met the criteria for ADHD diagnosis. Each subject took Bf-688, with one sachet in the morning and one in the evening (daily bacteria count 5 × 109 CFUs), for 8 weeks. Patients' clinical symptoms were assessed using the Swanson, Nolan, and Pelham Rating Scale (SNAP-IV). We collected stool samples at the baseline, the 8th week, and the 12th week for gut microbiota examination. During the 8-week Bf-688 supplement period, patients' inattention symptoms and hyperactivity/impulsiv2022-01-01T00:00:00Z2022 Feb2025-08-31T03:06:17.252Z2025-04-04T13:20:51.191ZS-EPMC88778793520771510.3390/jpm12020227